Azenta

Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Azenta (AZTA) reports robust Q1 earnings, eyes strategic investments

Azenta's Q1 results showcase strong revenue growth and strategic acquisitions, positioning the company for future success. While facing challenges in certain segments, the focus on investments and efficiencies presents opportunities for growth and margin improvement.

Azenta reports mixed Q2 results, focuses on growth initiatives

Azenta's Q2 2023 performance was mixed, with challenges in B Medical impacting revenue but Services business showing resilience and genomics revenue rebounding positively.
Strategic acquisitions, cost actions, and a realignment initiative aim to enhance profitability and drive growth, with a focus on accelerating organic growth and expanding Services business.
Despite margin decreases and revenue challenges, Azenta remains focused on growth initiatives, addressing concerns about distractions and emphasizing opportunities for expansion and profitability.
Management's outlook includes revised revenue guidance, adjusted EBITDA margin expectations, and a commitment to driving profitability through growth initiatives and cost actions.

Azenta reports solid Q3 earnings, eyes growth in China

Azenta's Q3 performance showcased positive financial indicators, with notable growth in key segments and a focus on cost reduction initiatives.
While facing challenges in the Products segment and market share determination, the company remains optimistic about growth opportunities in China and key service offerings.
With a strong focus on sales, marketing, and cost reduction, Azenta aims to sustain its growth trajectory and enhance profitability in the future.

Azenta reports robust Q4 earnings, eyes growth opportunities in 2024

Azenta's Q4 performance was strong, with positive outlook for fiscal 2024 and a commitment to share repurchase.
While facing challenges in gross margins, the company sees opportunities in organic growth and margin expansion.
Strengthening Cell and Gene Therapy business and operational improvements are key focus areas for future growth.
Overall, Azenta remains confident in its ability to outperform the market and enhance profitability.

Azenta reports Q1 revenue decline but sees growth opportunities ahead

Azenta's Q1 performance showed mixed results with revenue decline but growth in key segments. The company remains focused on maintaining guidance and balancing revenue throughout the year.
While facing challenges in B Medical revenue and market dynamics, Azenta has opportunities in sample retrieval programs and financial performance improvements.
Overall, Azenta's strategic focus on key segments and opportunities for growth position the company well for future success, despite current challenges and market conditions.

Azenta reports solid Q2 earnings, eyes growth in China

Azenta's Q2 performance showed revenue growth and improved margins despite challenges.
The company's strengths lie in strong segment growth and market outperformance in China.
Challenges include lower guidance for B Medical and softness in the Instruments segment.
Opportunities arise from pursuing Ascend 2026 plan, NGS shift, and China market growth.

Azenta reports strong Q3 performance and operational profitability growth

Azenta's Q3 results reflect a positive trajectory with revenue growth and improved profitability.
Strategic focus on key segments and the Ascend 2026 program are driving operational efficiency and margin expansion.
While challenges exist in certain segments, opportunities for growth and optimization present a promising outlook for Azenta.

Azenta reports resilient Q4 performance and outlines growth strategies

Azenta's Q4 2024 earnings call highlighted strong financial results, strategic decisions, and future growth initiatives amidst market challenges and uncertainties.
The company's focus on core businesses, competitive strengths in Sample Management Solutions and Multiomics, and commitment to shareholder value enhancement position it for success in 2025.
While facing revenue declines and market-related queries, Azenta's proactive approach to portfolio optimization, operational efficiency, and capital allocation sets the stage for sustainable growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brooks Automation

CHELMSFORD, Mass. , Oct. 3, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has closed its previously announced acquisition of B Medical Systems S.

Azenta Announces Completion of B Medical Systems Acquisition

CHELMSFORD, Mass. , Sept. 6, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Baird 2022 Global Healthcare Conference in New York City, on Wednesday, September 14, 2022, which includes a presentation beginning at 9:40 am ET.

Azenta to Participate in the Baird 2022 Global Healthcare Conference

CHELMSFORD, Mass. , Aug. 30, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York City, on Tuesday, September 13, 2022, which includes a presentation beginning at 4:40 pm ET.

Azenta to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

CHELMSFORD, Mass. , Aug. 11, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022.

Azenta to Participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Azenta, Inc. (NASDAQ:AZTA ) Q3 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Sara Silverman - Director, IR Steve Schwartz - President & CEO Lindon Robertson - EVP & CFO Matt McManus - COO Conference Call Participants Jacob Johnson - Stephens Paul Knight - KeyBanc Vijay Kumar - Evercore ISI David Saxon - Needham Yuan Zhi - B. Riley Securities Operator Greetings, and welcome to the Azenta Q3 2022 Financial Results.

Azenta, Inc. (AZTA) CEO Steve Schwartz on Q3 2022 Results - Earnings Call Transcript

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Azenta (AZTA) Q3 Earnings Beat Estimates

CHELMSFORD, Mass. , Aug. 9, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2022.

Azenta Life Sciences Reports Results of Third Quarter of Fiscal 2022, Ended June 30, 2022

Enhances Azenta's Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass. , Aug. 8, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.

Azenta Announces Agreement to Acquire B Medical Systems

CHELMSFORD, Mass. , Aug. 5, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, CA, on Thursday, August 11, 2022, which includes a presentation beginning at 4:00 pm PT.

Azenta to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit

CHELMSFORD, Mass. , July 27, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the opening of its new China headquarters in Suzhou, which serves as the hub for Azenta operations in the Asia Pacific region.

Azenta Celebrates Opening of New China Headquarters

The company's underwhelming third-quarter earnings forecast is weighing on its shares.

Why Azenta Stock Is Tumbling Today

Azenta, Inc. (NASDAQ AZTA) reported preliminary results for the third quarter. It expects revenue of ~$133 million, an increase of 3% year-over-year, versus the consensus of $143.52 million.

Azenta Shares Plunge After Q3 Preliminary Results

CHELMSFORD, Mass. , July 13, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported preliminary results for its third fiscal quarter ended June 30, 2022.

Azenta Reports Preliminary Results for Third Quarter of Fiscal 2022, Ended June 30, 2022 and Announces Earnings Conference Call and Webcast

CHELMSFORD, Mass. , July 1, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has closed its previously announced acquisition of Barkey Holding GmbH and its subsidiaries ("Barkey"), a leading provider of controlled rate thawing devices for customers in the medical, biotech and pharmaceutical industries.

Azenta Announces Completion of Barkey Holding GmbH Acquisition

CHELMSFORD, Mass. , June 8, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire Barkey Holding GmbH and its subsidiaries ("Barkey"), a leading provider of controlled rate thawing devices to medical, biotech and pharma industries.

Azenta Announces Agreement to Acquire Barkey Holding GmbH

CHELMSFORD, Mass. , May 19, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the UBS Global Healthcare Conference in New York, on Tuesday, May 24, 2022, which includes a presentation beginning at 2:45 pm ET.

Azenta to Participate in the UBS Global Healthcare Conference

Brooks (AZTA) delivered earnings and revenue surprises of 9.09% and 2.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Azenta (AZTA) Beats Q2 Earnings and Revenue Estimates

Azenta, Inc. (NASDAQ:AZTA ) Q2 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Sara Silverman - Director, Investor Relations Steve Schwartz - President & Chief Executive Officer Lindon Robertson - Executive Vice President & Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Paul Knight - KeyBanc Jacob Johnson - Stephens Joseph Conway - Needham Yuan Zhi - B. Riley Securities Operator Greetings, and welcome to the Azenta Q2 2022 Financial Results.

Azenta, Inc. (AZTA) CEO Steve Schwartz on Q2 2022 Results - Earnings Call Transcript

Robust customer demand bolstered by operational execution drives strong second quarter results CHELMSFORD, Mass., May 9, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported preliminary financial results for the second quarter ended March 31, 2022.

Azenta Life Sciences Reports Preliminary Results of Second Quarter of Fiscal 2022, Ended March 31, 2022

CHELMSFORD, Mass., April 28, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has rescheduled the release of its earnings for the second fiscal quarter of 2022 which ended on March 31, 2022 from Tuesday, May 3, 2022 to Monday, May 9, 2022 after the market closes.

Azenta Reschedules Fiscal 2022 Second Quarter Earnings Conference Call and Webcast

CHELMSFORD, Mass. , April 14, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal 2022 second quarter earnings which ended on March 31, 2022 on Tuesday, May 3, 2022 after the market closes.

Azenta Life Sciences Announces Fiscal 2022 Second Quarter Earnings Conference Call and Webcast

CHELMSFORD, Mass. , March 30, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, which includes a presentation beginning at 9:30am ET.

Azenta to Participate in the 21st Annual Needham Virtual Healthcare Conference

CHELMSFORD, Mass., March 11, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 22, 2022, which includes a presentation beginning at 3:00pm ET.

Azenta to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

CHELMSFORD, Mass., March 1, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022, which includes a presentation beginning at 10:15am ET.

Azenta to Participate in the Barclays Global Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Brooks (AZTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Azenta Stock (AZTA)